Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

KENILWORTH, N.J., July 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 second quarter.

"Our successful diversification strategy and strong execution by our people have given us the strength to again power through tough challenges - delivering operational sales growth and reconciled earnings-per-share growth for the second quarter," said Fred Hassan, chairman and CEO.

"Meantime, we can see that six years of focus and investment in our R&D pipeline have created enormous long-term value," said Hassan. "Our rich late-stage pipeline continues to advance. We continue to achieve positive regulatory actions in major markets - for example, the recent approval of two products - ASMANEX and REMERON - on the same day in Japan, and a recommendation for approval in Europe of SIMPONI, a novel biologic treatment for inflammatory diseases. In our industry, long-term strength comes from creating a continuous flow of new innovations. We are proud that we have created such a strong and productive R&D engine at Schering-Plough."

For the 2009 second quarter, Schering-Plough reported net income available to common shareholders of $633 million or 38 cents per common share on a GAAP basis. Earnings per common share for the 2009 second quarter would have been 46 cents on net income of $769 million on a reconciled basis, which excludes purchase accounting adjustments related to the acquisition of Organon BioSciences (OBS) and special, merger- and acquisition-related items. For the 2008 second quarter, Schering-Plough reported net income available to common shareholders of $424 million or 26 cents per common share on a GAAP basis and earnings of 45 cents per common share on a reconciled basis.

GAAP net sales for the 2009 second quarter totaled $4.6 billion, down 6 percent as compared to the second quarter of 2008, reflecting operational growth of 4 percent and an unfavorable impact from foreign exchange of 10 percent during the quarter.

Net sales of the cholesterol joint venture with Merck & Co., Inc., which include VYTORIN and ZETIA, totaled $1.0 billion in the 2009 second quarter. Schering-Plough does not record sales of its cholesterol joint venture with Merck as the venture is accounted for under the equity method. Including an adjustment of an assumed 50 percent of the global cholesterol joint venture net sales, Schering-Plough's adjusted net sales for the 2009 second quarter would have been $5.2 billion.

"Our diverse product strength - from REMICADE to TEMODAR to NUVARING to MIRALAX - and our rich geographic diversity helped drive our operational growth. In fact, we grew sales in most regions around the world on an operational basis. Achieving operational growth on such a broad front in the midst of a severe global recession is no small feat," said Hassan.

Regarding the company's R&D strength, the company highlighted its strong R&D engine and steady product flow as a special asset at a time when R&D innovation in the industry is so critical. The company noted that the "Five Stars" in its product pipeline, highlighted at its November 2008 R&D Update meeting, continued to advance: thrombin receptor antagonist (TRA), in Phase III for atherothrombosis; SIMPONI (golimumab), a subcutaneous treatment for certain inflammatory diseases; SAPHRIS (asenapine), for the acute treatment of schizophrenia and bipolar disorder; boceprevir, a protease inhibitor in Phase III for hepatitis C; and BRIDION (sugammadex), an innovative agent for use in anesthesiology.

The company's R&D engine has produced a number of recent regulatory and pipeline advances, including:

  • Approvals in Japan, the world's second-largest pharmaceutical market, in July of ASMANEX (mometasone furoate) for asthma and REMERON (mirtazapine) for depression; these approvals bring the number of new products approved in Japan to eight since the beginning of 2007;
  • Positive opinion from the EU's regulatory authority in June recommending approval of SIMPONI as a once-monthly, subcutaneous therapy for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis; SIMPONI was also launched in Canada in June as the first once-monthly subcutaneous treatment;
  • Acceptance for review by the European Medicines Agency (EMEA) in June of the marketing application for asenapine (to be marketed as SYCREST in Europe) sublingual tablets for schizophrenia and bipolar I disorder;
  • Initiation of patient enrollment in a Phase III trial (RED-CABG) in May for acadesine, an investigational, potentially first-in-class adenosine regulating agent for use in heart bypass surgery; and
  • In Animal Health, the launch of the first vaccine against canine influenza virus, which was granted a conditional product license by the U.S. Department of Agriculture (USDA) in May.

Regarding the planned merger with Merck announced on March 9, 2009, the company noted that pre-integration planning teams at both Schering-Plough and Merck have been meeting collaboratively to plan for a smooth and effective integration. The merger is expected to close in the fourth quarter of 2009. Until the merger closes, both companies will continue to operate independently.

Second Quarter 2009 Results

For the 2009 second quarter, Schering-Plough reported net income available to common shareholders of $633 million or 38 cents per common share on a GAAP basis. Earnings per common share for the 2009 second quarter would have been 46 cents on net income of $769 million on a reconciled basis, which excludes purchase accounting adjustments related to the OBS acquisition and special, merger- and acquisition-related items. For the 2008 second quarter, Schering-Plough reported net income available to common shareholders of $424 million or 26 cents per common share on a GAAP basis and earnings of 45 cents per common share on a reconciled basis.

GAAP net sales for the 2009 second quarter totaled $4.6 billion, down 6 percent as compared to the second quarter of 2008, reflecting operational growth of 4 percent and an unfavorable impact from foreign exchange of 10 percent during the quarter.

Net sales of the cholesterol franchise, which include sales of the cholesterol joint venture plus sales recorded by Schering-Plough in non-joint venture territories (such as Japan and Latin America), declined 8 percent in the second quarter of 2009 to $1.1 billion, reflecting a 2 percent operational decrease and a 6 percent unfavorable impact from foreign exchange. Sales declined 10 percent in the U.S. In international markets, sales declined 4 percent, reflecting operational growth of 10 percent and a 14 percent unfavorable impact from foreign exchange. ZETIA in Japan, sold under a co-marketing agreement with Bayer, contributed $41 million to cholesterol franchise sales in the 2009 period.

Sales of Prescription Pharmaceuticals for the 2009 second quarter decreased 3 percent to $3.6 billion, reflecting 7 percent operational growth and an unfavorable impact from foreign exchange of 10 percent.

Sales of REMICADE increased 2 percent (19 percent operational growth offset by 17 percent unfavorable foreign exchange impact) to $565 million in the second quarter of 2009 due to continued market growth. REMICADE is a treatment for inflammatory diseases that Schering-Plough markets in countries outside the U.S. (except in Japan and certain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, pediatric Crohn's disease and ulcerative colitis.

Global sales of NASONEX, an inhaled nasal corticosteroid for allergies, increased 3 percent to $321 million in the 2009 second quarter (10 percent operational growth offset by 7 percent unfavorable foreign exchange impact) as compared to $311 million in the second quarter of 2008. Operational sales were strong in both the U.S. and internationally as compared to the 2008 period.

Sales of TEMODAR, a treatment for certain types of brain tumors, increased 2 percent (11 percent operational growth offset by 9 percent unfavorable foreign exchange impact) to $256 million, with higher sales in the U.S. and Japan.

Sales of PEGINTRON for hepatitis C decreased 6 percent to $215 million in the 2009 second quarter, primarily due to the unfavorable foreign exchange impact of 6 percent.

In women's health care, sales of FOLLISTIM/PUREGON, a fertility treatment, for the second quarter of 2009 decreased 11 percent (1 percent operational decrease and 10 percent unfavorable foreign exchange impact) to $145 million as compared to the second quarter of 2008. Sales of NUVARING, a contraceptive product, in the second quarter of 2009 increased 11 percent (19 percent operational growth offset by 8 percent unfavorable foreign exchange impact) to $129 million as compared to $116 million in the second quarter of 2008.

Global sales of CLARINEX, a nonsedating antihistamine, were $226 million, a decrease of 6 percent (4 percent operational growth offset by 10 percent unfavorable foreign exchange impact) as compared to the second quarter of 2008.

Sales of CLARITIN in the prescription business were $96 million, a 13 percent decrease (6 percent operational decrease and 7 percent unfavorable foreign exchange impact) compared to sales of $111 million in the second quarter of 2008.

Animal Health sales totaled $677 million in the 2009 second quarter, a 17 percent decrease as compared to $818 million in the second quarter of 2008 (7 percent operational decrease and 10 percent unfavorable foreign exchange impact). The sales decline was a result of the overall economic environment, difficult comparisons against the 2008 launch of bluetongue vaccine and the impact of 2008 product divestitures.

Consumer Health Care sales were $381 million in the 2009 second quarter, down 5 percent versus the 2008 period. The decrease was primarily due to lower sales of sun care products, which primarily reflected the impact of unseasonable weather conditions in many parts of the U.S. Higher sales of MIRALAX helped offset lower sales of OTC CLARITIN.

Schering-Plough does not record sales of its cholesterol joint venture and incurs substantial costs such as selling, general and administrative costs that are not reflected in "Equity income" and are borne by the overall cost structure of Schering-Plough. As a result, Schering-Plough's gross margin and ratios of selling, general and administrative (SG&A) expenses and R&D expenses as a percentage of sales do not reflect the benefit of the impact of the cholesterol joint venture's operating results.

Schering-Plough's gross margin on a GAAP basis was unfavorably affected by purchase accounting adjustments and totaled 65.1 percent for the 2009 second quarter as compared to 61.2 percent in the 2008 period. On a reconciled basis, the gross margin percentage decreased to 68.1 percent for the second quarter of 2009 as compared to 68.4 percent for the second quarter of 2008, primarily due to the unfavorable impact from foreign exchange.

SG&A expenses were $1.6 billion in the second quarter of 2009, a 13 percent decrease versus the second quarter of 2008 primarily due to the impact of foreign exchange and the company's Productivity Transformation Program (PTP).

Research and development spending for the 2009 second quarter totaled $863 million, a 5 percent decrease, primarily due to the impact of foreign exchange.

Recent Developments

In addition to the regulatory and pipeline advances discussed above, the company also offered the following summary of recent significant developments that have previously been announced, including:

  • Presented Phase II results of the HCV SPRINT-1 study showing that boceprevir, an oral hepatitis C protease inhibitor, in combination with peginterferon alfa-2b and ribavirin significantly increased sustained virologic response compared to current standard of care. (Announced April 23)
  • Announced changes to the company's global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease. (Announced May 19)
  • Reported that Johnson & Johnson, as a result of the proposed merger between Schering-Plough and Merck, has initiated arbitration proceedings relating to Schering-Plough's rights to REMICADE and SIMPONI. (Announced May 27)
  • Announced that the EMEA had accepted for review the Marketing Authorization Application for SYCREST (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder. (Announced June 2)
  • Reported findings from extensions of two Phase III studies showing that subcutaneous injections of SIMPONI every four weeks provided persistent improvements in the signs and symptoms in patients with psoriatic arthritis and ankylosing spondylitis. Separately, a new analysis was reported showing that a greater proportion of anti-TNF-experienced patients with moderately to severely active rheumatoid arthritis who received subcutaneous injections of SIMPONI every four weeks experienced significant improvements in signs and symptoms compared with patients receiving placebo. (Announced June 10)
  • With Merck, reported the receipt of a request for additional information from the U.S. Federal Trade Commission with respect to the previously announced proposed merger. (Announced June 22)
  • Santarus, Inc. announced that Schering-Plough HealthCare Products, Inc. had received notification from the FDA of a December 2009 action date for an over-the-counter ZEGERID branded omeprazole/sodium bicarbonate product. (Announced June 23)
  • Schering-Plough and Merck scheduled special meetings of shareholders on Aug. 7, 2009, for purposes of voting on the proposed merger. The transaction is subject to shareholder approvals as well as the satisfaction of customary closing conditions and regulatory approvals, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as clearance by the European Commission under the EC Merger Regulation and certain other foreign jurisdictions. (Announced June 25)
  • Reported results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. (Announced July 1)
  • Extended to stage two an ongoing Phase II clinical study with vicriviroc, an investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. (Announced July 15)
  • Merck and Schering-Plough and the companies' cholesterol joint venture, Merck/Schering-Plough Pharmaceuticals, reached a civil settlement with a multistate group of attorneys general representing 35 states and the District of Columbia who investigated whether the companies violated state consumer protection laws in connection with the ENHANCE clinical trial or by their promotion and marketing of VYTORIN and ZETIA. (Announced July 15)

Second Quarter 2009 Conference Call and Webcast

Schering-Plough will conduct a conference call today at 7:45 a.m. (EDT) to review the 2009 second quarter results. To listen live to the call, dial 1-866-871-2144 or 1-706-634-5003 and enter conference ID # 13268740. A replay of the call will be available beginning later on July 21 through 5 p.m. on Tuesday, July 28. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID # 13268740. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on July 21 through 5 p.m. on Aug. 21.

DISCLOSURE NOTICE:

The information in this press release, the comments of Schering-Plough officers during the earnings teleconference/webcast on July 21, 2009, beginning at 7:45 a.m. (EDT), and other written reports and oral statements made from time to time by the company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and are based on current expectations or forecasts of future events. You can identify these forward-looking statements by their use of words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "project," "intend," "plan," "potential," "will," and other similar words and terms. In particular, forward-looking statements include statements relating to the company's plans; its strategies; business prospects; anticipated growth; timing and level of savings achieved from the Productivity Transformation Program; prospective products or product approvals; trends in performance; anticipated timing of clinical trials and its impact on R&D spending; anticipated exclusivity periods; the potential of products and trending in therapeutic markets, including the cholesterol market; and statements about the timing and potential benefits of the proposed merger between Merck and Schering-Plough and other statements that are not historical facts. Actual results may vary materially from the company's forward-looking statements, and there are no guarantees about the performance of Schering-Plough stock or Schering-Plough's business. Schering-Plough does not assume the obligation to update any forward-looking statement.

A number of risks and uncertainties could cause results to differ materially from forward-looking statements, including, among other uncertainties, market viability of the company's (and the cholesterol joint venture's) marketed and pipeline products; market forces; economic factors such as interest rate and exchange rate fluctuations; the outcome of contingencies such as litigation and investigations; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the regulatory process (including product approvals, labeling and post-marketing actions); scientific developments relating to marketed products or pipeline projects; media and societal reaction to such developments; and the ability of Schering-Plough and Merck to obtain governmental and self-regulatory organization approvals of the merger on the proposed terms and schedule. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A "Risk Factors" in the company's first quarter 2009 10-Q, filed May 1, 2009.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


    SCHERING-PLOUGH CORPORATION
    U.S. GAAP report for the second quarter ended June 30 (unaudited):
    (Amounts in millions, except per share figures)

                                           Second Quarter       Six Months
                                           --------------       ----------
                                           2009       2008    2009       2008
                                           ----       ----    ----       ----
     Net sales                           $4,647     $4,921  $9,040     $9,577
     Cost of sales 1/                     1,620      1,908   3,019      4,044
    Selling, general and administrative   1,626      1,870   3,119      3,547
    Research and development                863        906   1,667      1,786
    Other expense/(income), net             106        134     194        229
    Special, merger and
     acquisition-related charges 2/          29         94     104        117
    Equity income 3/                       (370)      (493)   (770)    (1,010)
                                          -----      -----   -----    -------

    Income before income taxes              773        502   1,707        864
    Income tax expense                      102         40     231         89
                                            ---         --     ---         --
    Net income                             $671       $462  $1,476       $775
                                           ====       ====  ======       ====

    Preferred stock dividends                38         38      75         75
                                             --         --      --         --
    Net income available to common
     shareholders                          $633       $424  $1,401       $700
                                           ====       ====  ======       ====

    Diluted earnings per common share 4/  $0.38      $0.26   $0.85      $0.43
                                          =====      =====   =====      =====

    Average shares outstanding - common
     and participating - diluted 4/       1,658      1,632   1,744      1,635

    Note: The Company incurs substantial costs related to the cholesterol
    joint venture, such as selling, general and administrative costs, that
    are not reflected in the "Equity income" and are borne by the overall
    cost structure of Schering-Plough.

    1/ Cost of sales for the three months ended June 30, 2009 and 2008
    include purchase accounting adjustments of $131 million and $354 million,
    respectively. For the six months ended June 30, 2009 and 2008, cost of
    sales includes purchase accounting adjustments of $256 million and $1.0
    billion, respectively.

    2/ Special, merger and acquisition-related charges relate to the
    Productivity Transformation Program (PTP) and costs incurred related to
    the proposed merger with Merck. For the three months ended June 30, 2009
    and 2008 these charges were $29 million ($18 million for severance costs
    and $11 million for merger costs) and $94 million ($77 million for
    severance costs and $17 million for integration-related costs),
    respectively. For the six months ended June 30, 2009 and 2008 these
    charges were $104 million ($74 million for severance costs and $30 million
    for merger costs) and $117 million ($84 million for severance costs and
    $33 million for integration-related costs), respectively.

    3/ Included in Equity income for the three and six months ended June 30,
    2008 was $64 million of income related to the termination of a
    respiratory joint venture with Merck.

    4/ Diluted EPS for the three months ended June 30, 2009 is calculated
    based on net income available to common shareholders and average diluted
    shares - common and participating - outstanding. For the three months
    ended June 30, 2009, approximately 91 million common shares obtainable
    upon conversion of Schering-Plough's 2007 mandatory convertible preferred
    stock were excluded from the computation of diluted EPS because their
    effect would have been antidilutive. For the six months ended June 30,
    2009, diluted EPS is calculated based on net income and average diluted
    shares - common and participating - outstanding. For the six months ended
    June 30, 2009, approximately 91 million common shares obtainable upon
    conversion of Schering-Plough's 2007 mandatory convertible preferred stock
    were included in the computation of diluted EPS because their effect would
    have been dilutive.



    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to Common Shareholders and Diluted Earnings per
    Common Share
    (Amounts in Millions, except per share figures)

    To supplement its consolidated financial statements presented in
    accordance with accounting principles generally accepted in the United
    States of America (U.S. GAAP), Schering-Plough is providing the
    supplemental financial information below and on the following pages to
    reflect "As Reconciled" amounts related to Net income available to common
    shareholders and Diluted earnings per common share.  "As Reconciled"
    amounts exclude the effects of purchase accounting adjustments, special
    and acquisition-related items and other specified items.

    "As Reconciled" amounts related to Net income available to common
    shareholders and Diluted earnings per common share are non-U.S. GAAP
    measures used by management in evaluating the performance of
    Schering-Plough's  overall business.  The effects of purchase accounting
    adjustments, special and acquisition-related items and other specified
    items have been excluded from Net income available to common shareholders
    and Diluted earnings per common share as management of Schering-Plough
    does not consider these charges to be indicative of continuing operating
    results.  Schering-Plough believes that these "As Reconciled" performance
    measures contribute to a more complete understanding by investors of the
    overall results of the company and enhances investor understanding of
    items that impact the comparability of results between fiscal periods.
    Net income available to common shareholders and Diluted earnings per
    common share, as reported, are required to be presented under U.S. GAAP.


                                  Three months ended June 30, 2009
                                              (unaudited)
                                              -----------
                                               Special,
                                  Purchase    Merger and
                                 Accounting  Acquisition-   Other       As
                         As       Adjust-      Related    Specified Reconciled
                      Reported     ments        Items       Items      (1)
                      --------     -----        -----       -----      ---
    Net sales            $4,647          $-           $-        $-    $4,647
    Cost of sales         1,620        (131)          (5)        -     1,484
    Selling,
     general and
    administrative        1,626          (1)           -         -     1,625
    Research and
     development            863          (3)           -         -       860
    Other expense/
     (income), net          106           -            -         -       106
    Special, merger and
    acquisition-related
     charges                 29           -          (29)        -         -
    Equity income          (370)          -            -         -      (370)
                          -----           -            -         -     -----

    Income before
     income taxes           773         135           34         -       942
    Income tax
    expense/(benefit)       102         (27)          (6)        -       135
                            ---        ----          ---         -       ---

    Net income             $671        $108          $28        $-      $807
                           ----        ----          ===        --      ----

    Preferred stock
     dividends               38           -            -         -        38
                             --           -            -         -        --
    Net income available
     To common
     shareholders          $633        $108          $28        $-      $769
                           ====        ====          ===        ==      ====

    Diluted earnings per
     common share (2)     $0.38                                        $0.46
                          =====                                        =====

    Average shares
     outstanding
     common and
     participating
     - diluted (2)        1,658                                        1,658

    (1)  "As Reconciled" to exclude purchase accounting adjustments, special,
    merger and acquisition-related items and other specified items.

    (2)  Diluted EPS for the three months ended June 30, 2009 is calculated
    based on net income available to common shareholders and average diluted
    shares - common and participating - outstanding. For the three months
    ended June 30, 2009, approximately 91 million common shares obtainable
    upon conversion of Schering-Plough's 2007 mandatory convertible preferred
    stock were excluded from the computation of diluted EPS because their
    effect would have been antidilutive.


    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to Common Shareholders and Diluted Earnings per
    Common Share
    (Amounts in Millions, except per share figures)

                                 Three months ended June 30, 2008
                                            (unaudited)
                                            -----------
                                              Special
                                 Purchase       and
                                Accounting  Acquisition-   Other      As
                         As      Adjust-      Related    Specified Reconciled
                      Reported    ments        Items       Items      (1)
                      --------    -----        -----       -----      ---
    Net sales           $4,921        $-           $-        $-    $4,921
    Cost of sales        1,908      (354)           -         -     1,554
    Selling,
     general and
    administrative       1,870         (1)           -         -     1,869
    Research and
     development           906         (2)           -         -       904
    Other
    expense/(income),
     net                   134          -            -         -       134
    Special and
    acquisition-related
     charges                94          -          (94)        -         -
    Equity income         (493)         -            -        64      (429)
                         -----          -            -        --     -----

    Income before
     income taxes          502        357           94       (64)      889
    Income tax
    expense/(benefit)       40        (73)          (7)        -       120
                            --       ----          ---         -       ---

    Net income            $462       $284          $87      $(64)     $769
                          ----       ----          ===      ----      ----

    Preferred
     stock
     dividends              38          -            -         -        38
                            --          -            -         -        --
    Net income
     available to
     common
     shareholders         $424       $284          $87      $(64)     $731
                          ====       ====          ===      ====      ====

    Diluted
     earnings per
     common share        $0.26                                       $0.45
                         =====                                       =====

    Average shares
     outstanding
     common and
     participating
     - diluted           1,632                                       1,632

    (1)  "As Reconciled" to exclude purchase accounting adjustments, special
    and acquisition-related items and other specified items.



    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to Common Shareholders and Diluted Earnings per
    Common Share
    (Amounts in Millions, except per share figures)

                                    Six months ended June 30, 2009
                                             (unaudited)
                                             -----------
                                               Special,
                                  Purchase    Merger and
                                 Accounting  Acquisition-   Other       As
                         As       Adjust-      Related    Specified Reconciled
                      Reported     ments        Items       Items       (1)
                      --------     -----        -----       -----       ---
    Net sales           $9,040          $-           $-        $-    $9,040
    Cost of sales        3,019        (256)          (7)        -     2,756
    Selling,
     general and
    administrative       3,119          (3)           -         -     3,116
    Research and
     development         1,667          (5)          (2)        -     1,660
    Other
    expense/(income),
     net                   194           -            -         -       194
    Special,
     merger and
    acquisition-related
     charges               104           -         (104)        -         -
    Equity income         (770)          -            -         -      (770)
                         -----           -            -         -     -----

    Income before
     income taxes        1,707         264          113         -     2,084
    Income tax
     expense/(benefit)     231         (59)         (13)        -       303
                           ---        ----         ----         -       ---

    Net income          $1,476        $205         $100        $-    $1,781
                        ------        ----         ----        --    ------

    Preferred stock
     dividends              75           -            -         -        75
                            --           -            -         -        --
    Net income
     available to
     common
     shareholders       $1,401        $205         $100        $-    $1,706
                        ======        ====         ====        ==    ======

    Diluted earnings
     Per common share
      (2)                $0.85                                        $1.02
                         =====                                        =====

     Average shares
      outstanding
      common and
      participating
      - diluted (2)      1,744                                        1,744

    (1) "As Reconciled" to exclude purchase accounting adjustments, special,
    merger and acquisition-related items and other specified items.

    (2) Diluted EPS for the six months ended June 30, 2009 is calculated
    based on net income and average diluted shares - common and
    participating - outstanding. For the six months ended June 30, 2009,
    approximately 91 million common shares obtainable upon conversion of
    Schering-Plough's 2007 mandatory convertible preferred stock were
    included in the computation of diluted EPS because their effect would
    have been dilutive.



    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to Common Shareholders and Diluted Earnings per
    Common Share
    (Amounts in Millions, except per share figures)

                                    Six months ended June 30, 2008
                                             (unaudited)
                                             -----------
                                                Special
                                  Purchase        and
                                 Accounting  Acquisition-   Other       As
                         As       Adjust-      Related    Specified Reconciled
                      Reported     ments        Items       Items      (1)
                      --------     -----        -----       -----      ---
    Net sales           $9,577          $-           $-        $-    $9,577
    Cost of sales        4,044      (1,042)           -         -     3,002
    Selling,
     general and
    administrative       3,547          (2)           -         -     3,545
    Research and
     development         1,786          (4)           -         -     1,782
    Other
    expense/(income),
     net                   229           -            -        17       246
    Special and
    acquisition-related
     charges               117           -         (117)        -         -
    Equity income       (1,010)          -            -        64      (946)
                       -------           -            -        --     -----

    Income before
     income taxes          864       1,048          117       (81)    1,948
    Income tax
    expense/(benefit)       89        (187)          (9)        5       280
                            --       -----          ---         -       ---

    Net income            $775        $861         $108      $(76)   $1,668
                          ----        ----         ----      ----    ------

    Preferred stock
     dividends              75           -            -         -        75
                            --           -            -         -        --
    Net income
     available to
     common
     shareholders         $700        $861         $108      $(76)   $1,593
                          ====        ====         ====      ====    ======

    Diluted
     earnings per
     common share        $0.43                                        $0.97
                         =====                                        =====

    Average shares
     outstanding
     common and
     participating
     - diluted           1,635                                        1,635

    (1) "As Reconciled" to exclude purchase accounting adjustments, special
    and acquisition-related items and other specified items.


    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to Common Shareholders and Diluted Earnings per
    Common Share
    (Amounts in Millions)

    "As Reconciled" amounts related to Net income available to common
    shareholders and Diluted earnings per common share reflect the following
    adjustments:

                                            Second Quarter      Six Months
                                              (unaudited)      (unaudited)
                                              -----------      -----------
                                            2009       2008   2009     2008
                                            ----       ----   ----     ----
    Purchase accounting adjustments:
    --------------------------------
         Amortization of intangibles in
          connection with the acquisition
          of Organon BioSciences (a)        $122       $138   $241     $270
         Depreciation related to the fair
          value adjustment of fixed
          assets related to the
          acquisition of Organon
          BioSciences (b)                     13          8     23       16
         Charge related to the fair value
          adjustment to inventory related
          to the acquisition of Organon
          BioSciences (a)                      -        211      -      762
                                               -        ---      -      ---
    Total purchase accounting
     adjustments, pre-tax                    135        357    264    1,048
         Income tax benefit                   27         73     59      187
                                              --         --     --      ---
    Total purchase accounting
     adjustments                            $108       $284   $205     $861
                                            ====       ====   ====     ====

    Special, merger and
     acquisition-related items:
    ---------------------------
         Accelerated depreciation (a)         $5         $-     $7       $-
         Special, merger and
          acquisition-related activities
          (d)/(e)                             29         94    106      117
                                              --         --    ---      ---
    Total special, merger and
     acquisition-related items,
     pre-tax                                  34         94    113      117
         Income tax benefit                    6          7     13        9
                                               -          -     --        -
    Total special, merger and
     acquisition-related items               $28        $87   $100     $108
                                             ===        ===   ====     ====

    Other specified items:
    ----------------------
         Income from respiratory JV
          termination (f)                     $-       $(64)    $-     $(64)
         (Gain) on sale of manufacturing
          plant (c)                            -          -      -      (17)
    Total other specified items,
     pre-tax                                   -          -      -      (81)
         Income tax expense                    -          -      -       (5)
                                               -          -      -      ---
    Total other specified items               $-       $(64)    $-     $(76)
                                              ==       ====     ==     ====

    Total purchase accounting
     adjustments, special, merger
     and acquisition-related items
     and other specified items              $136       $307   $305     $893
                                            ====       ====   ====     ====

    (a)  Included in cost of sales
    (b)  Included in cost of sales, selling, general and administrative and
         research and development
    (c)  Included in other expense (income), net
    (d)  Included in special, merger and acquisition-related charges
    (e)  Included in research and development
    (f)  Included in equity income


    SCHERING-PLOUGH CORPORATION

    Report for the period ended June 30 (unaudited):

    GAAP Net Sales by Key Product

    (Dollars in millions)         Second Quarter            Six Months
                                  --------------            ----------
                                   2009   2008      %     2009    2008    %
                                   ----   ----      -     ----    ----    -

    PRESCRIPTION PHARMACEUTICALS $3,589 $3,702     (3%) $6,968  $7,259   (4%)
       REMICADE                     565    557       2%  1,083   1,064     2%
       NASONEX                      321    311       3%    627     618     1%
       TEMODAR                      256    251       2%    503     487     3%
       PEGINTRON                    215    229     (6%)    430     454   (5%)
       CLARINEX / AERIUS            226    240     (6%)    400     454  (12%)
       FOLLISTIM / PUREGON          145    162    (11%)    275     308  (10%)
       NUVARING                     129    116      11%    244     212    15%
       CLARITIN Rx                   96    111    (13%)    228     239   (4%)
       AVELOX                        71     67       7%    180     209  (14%)
       INTEGRILIN                    73     78     (7%)    149     152   (2%)
       REBETOL                       67     70     (4%)    134     130     3%
       CAELYX                        68     78    (14%)    128     152  (16%)
       INTRON                        67     61      10%    121     116     4%
       PROVENTIL / ALBUTEROL         56     38      46%    110      89    24%
       ASMANEX                       54     48      12%    103      91    14%
       SUBUTEX / SUBOXONE            52     62    (15%)    102     115  (12%)
       REMERON                       50     61    (18%)    100     129  (22%)
       ELOCON                        45     47     (4%)     87      92   (6%)
       CERAZETTE                     46     49     (6%)     85      93   (8%)
       NOXAFIL                       43     38      14%     82      72    15%
       IMPLANON                      43     44     (1%)     80      82   (2%)
       MERCILON                      33     47    (30%)     68      90  (25%)
       LIVIAL                        39     50    (22%)     72      95  (24%)
       MARVELON                      36     40     (9%)     68      77  (13%)
       ZEMURON                       33     67    (51%)     65     130  (50%)
       FORADIL                       25     25     (1%)     48      51   (4%)
       Other Pharmaceuticals        735    755     (3%)  1,396   1,458   (4%)

    ANIMAL HEALTH                   677    818    (17%)  1,307   1,540  (15%)

    CONSUMER HEALTH CARE            381    401     (5%)    765     778   (2%)
       OTC                          184    181       2%    416     389     7%
            OTC CLARITIN            108    120    (10%)    257     258     -
            MiraLAX                  36     28      30%     73      54    36%
            Other OTC                40     33      22%     86      77    11%
       Foot Care                    101    105     (4%)    174     190   (8%)
       Sun Care                      96    115    (17%)    175     199  (12%)
                                     --    ---             ---     ---

    CONSOLIDATED GAAP NET SALES  $4,647 $4,921     (6%) $9,040  $9,577   (6%)
                                 ====== ======          ======  ======

    NOTES:
    -  GAAP net sales for the three months ended June 30, 2009 totaled $4.6
       billion, down 6 percent as compared to 2008, reflecting operational
       growth of 4 percent and an unfavorable impact from foreign exchange of
       10 percent.
    -  GAAP net sales for the six months ended June 30, 2009 totaled $9.0
       billion, down 6 percent as compared to 2008, reflecting operational
       growth of 4 percent and an unfavorable impact from foreign exchange
       of 10 percent.

    Additional information about U.S. and international sales for specific
    products is available by calling the company or visiting the Investor
    Relations Web site athttp://ir.schering-plough.com.

    SCHERING-PLOUGH CORPORATION

    Reconciliation of Non-U.S. GAAP Financial Measures

    Adjusted net sales, defined as Net sales plus an assumed 50 percent of
    global cholesterol joint venture net sales.


    (Dollars in millions)                       Three months ended June 30,
                                                       (unaudited)
                                                       -----------
                                              2009          2008      %
                                              ----          ----      -

    Net sales, as reported                  $4,647        $4,921      (6%)

    50 percent of cholesterol joint venture
     net sales  a/                             509           566     (10%)
                                               ---           ---     ----

    Adjusted net sales                      $5,156        $5,487      (6%)
                                            ======        ======      ===


                                                Six months ended June 30,
    (Dollars in millions)                             (unaudited)
                                                      -----------
                                               2009          2008      %
                                               ----          ----      -

    Net sales, as reported                   $9,040        $9,577      (6%)

    50 percent of cholesterol joint venture
     net sales  a/                              975         1,174     (17%)
                                                ---         -----     ----

    Adjusted net sales                      $10,015       $10,751      (7%)
                                            =======       =======      ===

    a/ Total Net sales of the cholesterol joint venture for the three months
    ended June 30, 2009 and 2008 were $1.0 billion and $1.1 billion,
    respectively.  Total Net sales of the cholesterol joint venture for the
    six months ended June 30, 2009 and 2008 were $1.9 billion and $2.3
    billion, respectively.

    NOTE:  Adjusted net sales, defined as net sales plus an assumed 50
    percent of global cholesterol joint venture net sales, is a non-U.S.
    GAAP measure used by management in evaluating the performance of the
    Schering-Plough's overall business.  Schering-Plough believes that this
    performance measure contributes to a more complete understanding by
    investors of the overall results of the company.  Schering-Plough
    provides this information to supplement the reader's understanding of
    the importance to the company of its share of results from the operations
    of the cholesterol joint venture.  Net sales (excluding the cholesterol
    joint venture net sales) is required to be presented under U.S. GAAP.
    The cholesterol joint venture's net sales are included as a component of
    income from operations in the calculation of Schering-Plough's "Equity
    income."  Net sales of the cholesterol joint venture do not include net
    sales of cholesterol products in non-joint venture territories.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved


Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... MANASSAS, Va. , Feb. 5, 2016 ... organization, is poised to assist the medical and life ... concerns around Zika Virus infection.   CDC ... --> Zika virus is a single-stranded ... also includes the West Nile, Dengue and Chikungunya Viruses. ...
(Date:2/4/2016)... San Francisco, CA (PRWEB) , ... February 04, ... ... future of enterprise talent development and compliance training, today announced an interactive ... on Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, ... various medical institutions attended a ceremony in late 2015 ... personalized cell therapy in 2016. --> ... Clinical Translation Platform for Personalized Cell Therapy" was hosted ... Cell Production Center, both subsidiaries of Beike Biotechnology Co., ...
(Date:2/4/2016)... 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today provided an update on the ... District of Texas and announcing ... Inter Partes Re-examination ("IPR") proceedings that VTech and ... was initiated on only certain claims of two of ...
Breaking Biology Technology:
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... BELL, Pa. , Jan. 25, 2016   Unisys Corporation ... recognition system at John F. Kennedy (JFK) International Airport, ... Border Protection (CBP) identify imposters attempting to enter ... do not belong to them. pilot testing of ... out initially at three terminals at JFK during January 2016. ...
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
Breaking Biology News(10 mins):